Could a new drug help keep myasthenia gravis symptoms at bay?
NCT ID NCT07673744
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether ublituximab, given as an infusion, can help adults with myasthenia gravis maintain symptom control after initial treatment with efgartigimod. Participants will receive either ublituximab or a placebo, and researchers will track how long it takes for symptoms to worsen. The goal is to see if ublituximab can delay or prevent flare-ups in this autoimmune disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ublituximab (BRIUMVI)
What this could lead to
If successful, this could provide a new maintenance option to help people with myasthenia gravis stay stable longer and delay symptom worsening.
What could go wrong
This is an early phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
TG Therapeutics Investigational Trial Site
RECRUITINGColorado Springs, Colorado, 80919, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGClearwater, Florida, 33761, United States